Messé M, Bernhard C, Foppolo S, Thomas L, Marchand P, Herold-Mende C, Idbaih A, Kessler H, Etienne-Selloum N, Ochoa C, Tambar UK, Elati M, Laquerriere P, Entz-Werle N, Martin S, Reita D, Dontenwill M

Biochim Biophys Acta Mol Basis Dis. 2024 08 16;:167471

Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids.

Conrad O, Burgy M, Foppolo S, Jehl A, Thiéry A, Guihard S, Vauchelles R, Jung AC, Mourtada J, Macabre C, Ledrappier S, Chenard MP, Onea MA, Danic A, Dourlhes T, Thibault C, Schultz P, Dontenwill M, Martin S

Int J Mol Sci. 2023 07 6;24(13):

Triphenylphosphonium-functionalized N-heterocyclic carbene platinum complexes [(NHC-TPP)Pt] induce cell death of human glioblastoma cancer stem cells.

Fernandez de Larrinoa P, Parmentier J, Kichler A, Achard T, Dontenwill M, Herold-Mende C, Fournel S, Frisch B, Heurtault B, Bellemin-Laponnaz S

Int J Pharm. 2023 05 25;:123071

Glioblastoma Metabolism: Insights and Therapeutic Strategies.

Bernhard C, Reita D, Martin S, Entz-Werle N, Dontenwill M

Int J Mol Sci. 2023 05 23;24(11):

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction.

Jehl A, Conrad O, Burgy M, Foppolo S, Vauchelles R, Ronzani C, Etienne-Selloum N, Chenard MP, Danic A, Dourlhes T, Thibault C, Schultz P, Dontenwill M, Martin S

Cells. 2023 02 24;12(5):

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.

Lhermitte B, Wolf T, Chenard MP, Coca A, Todeschi J, Proust F, Hirsch E, Schott R, Noel G, Guerin E, Reita D, Chammas A, Salmon A, Martin S, Dontenwill M, Entz-Werlé N

Cancers (Basel). 2023 02 16;15(4):

Evaluation of the Cytotoxicity of Cationic Polymers on Glioblastoma Cancer Stem Cells.

McCartin C, Blumberger J, Dussouillez C, Fernandez de Larrinoa P, Dontenwill M, Herold-Mende C, Lavalle P, Heurtault B, Bellemin-Laponnaz S, Fournel S, Kichler A

J Funct Biomater. 2022 12 28;14(1):

Challenges in glioblastoma research: focus on the tumor microenvironment.

Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, Ducray F, Enz-Werle N, Figarella-Branger D, Fournier I, Frenel JS, Gabut M, Galli T, Gavard J, Huberfeld G, Hugnot JP, Idbaih A, Junier MP, Mathivet T, Menei P, Meyronet D, Mirjolet C, Morin F, Mosser J, Moyal EC, Rousseau V, Salzet M, Sanson M, Seano G, Tabouret E, Tchoghandjian A, Turchi L, Vallette FM, Vats S, Verreault M, Virolle T

Trends Cancer. 2022 11 15;:

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells.

McCartin C, Dussouillez C, Bernhard C, Mathieu E, Blumberger J, Dontenwill M, Herold-Mende C, Idbaih A, Lavalle P, Bellemin-Laponnaz S, Kichler A, Fournel S

Cancers (Basel). 2022 10 15;14(20):

Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity.

Cruz Da Silva E, Foppolo S, Lhermitte B, Ingremeau M, Justiniano H, Klein L, Chenard MP, Vauchelles R, Abdallah B, Lehmann M, Etienne-Selloum N, Dontenwill M, Choulier L

Pharmaceutics. 2022 09 20;14(10):

An N-heterocyclic carbene iridium(III) complex as a potent anti-cancer stem cell therapeutic.

McCartin C, Mathieu E, Dontenwill M, Herold-Mende C, Idbaih A, Bonfiglio A, Mauro M, Fournel S, Kichler A

Chem Biol Interact. 2022 09 7;:110167

Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment.

Pierrevelcin M, Flacher V, Mueller CG, Vauchelles R, Guerin E, Lhermitte B, Pencreach E, Reisch A, Muller Q, Doumard L, Boufenghour W, Klymchenko AS, Foppolo S, Nazon C, Weingertner N, Martin S, Briandet C, Laithier V, Di Marco A, Bund L, Obrecht A, Villa P, Dontenwill M, Entz-Werlé N

Adv Healthc Mater. 2022 09 4;:e2200195

Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas.

Nazon C, Pierrevelcin M, Willaume T, Lhermitte B, Weingertner N, Marco AD, Bund L, Vincent F, Bierry G, Gomez-Brouchet A, Redini F, Gaspar N, Dontenwill M, Entz-Werle N

Cancers (Basel). 2022 Mar 14;14(6):

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.

Sani S, Pallaoro N, Messe M, Bernhard C, Etienne-Selloum N, Kessler H, Marinelli L, Entz-Werle N, Foppolo S, Martin S, Reita D, Dontenwill M

Cancers (Basel). 2022 Jan 12;14(2):

Advanced quantification for single-cell adhesion by variable-angle TIRF nanoscopy.

El Arawi D, Vézy C, Déturche R, Lehmann M, Kessler H, Dontenwill M, Jaffiol R

Biophys Rep (N Y). 2021 12 8;1(2):100021

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions.

Fuchs Q, Batut A, Gleyzes M, Rontard J, Miny L, Libralato M, Vieira J, Debis D, Larramendy F, Honegger T, Messe M, Pierrevelcin M, Lhermitte B, Dontenwill M, Entz-Werlé N

J Vis Exp. 2021 Nov 17;(177):

Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma.

Etienne-Selloum N, Prades J, Bello-Roufai D, Boone M, Sevestre H, Trudel S, Caillet P, Coutte A, Desenclos C, Constans JM, Martin S, Choulier L, Chauffert B, Dontenwill M

Pharmaceuticals (Basel). 2021 Aug 30;14(9):

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.

Burgy M, Jehl A, Conrad O, Foppolo S, Bruban V, Etienne-Selloum N, Jung AC, Masson M, Macabre C, Ledrappier S, Burckel H, Mura C, Noël G, Borel C, Fasquelle F, Onea MA, Chenard MP, Thiéry A, Dontenwill M, Martin S

Cancers (Basel). 2021 Jun 18;13(12):

A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value.

Entz-Werlé N, Poidevin L, Nazarov PV, Poch O, Lhermitte B, Chenard MP, Burckel H, Guérin E, Fuchs Q, Castel D, Noel G, Choulier L, Dontenwill M, Van Dyck E

Cancers (Basel). 2021 May 7;13(9):

A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.

Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L

Cancers (Basel). 2021 Apr 9;13(8):

Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells.

Blandin AF, Cruz Da Silva E, Mercier MC, Glushonkov O, Didier P, Dedieu S, Schneider C, Devy J, Etienne-Selloum N, Dontenwill M, Choulier L, Lehmann M

Cell Mol Life Sci. 2020 Nov 5;:

Biological relevance of RGD-integrin subtype-specific ligands in cancer.

Sani S, Messe M, Fuchs Q, Pierrevelcin M, Laquerriere P, Entz-Werle N, Reita D, Etienne-Selloum N, Bruban V, Choulier L, Martin S, Dontenwill M

Chembiochem. 2020 Nov 3;:

Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability.

Pierrevelcin M, Fuchs Q, Lhermitte B, Messé M, Guérin E, Weingertner N, Martin S, Lelong-Rebel I, Nazon C, Dontenwill M, Entz-Werlé N

Cells. 2020 Aug 31;9(9):

Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes.

Harmouch E, Seitlinger J, Chaddad H, Ubeaud-Sequier G, Barths J, Saidu S, Désaubry L, Grandemange S, Massfelder T, Fuhrmann G, Fioretti F, Dontenwill M, Benkirane-Jessel N, Idoux-Gillet Y

Sci Rep. 2020 Aug 13;10(1):13750

Hypoxia Inducible Factors' Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches.

Fuchs Q, Pierrevelcin M, Messe M, Lhermitte B, Blandin AF, Papin C, Coca A, Dontenwill M, Entz-Werlé N

Cancers (Basel). 2020 Apr 15;12(4):

Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric -Mutated Gliomas Recreate the Patient Tumor Complexity.

Blandin AF, Durand A, Litzler M, Tripp A, Guérin É, Ruhland E, Obrecht A, Keime C, Fuchs Q, Reita D, Lhermitte B, Coca A, Jones C, Rebel IL, Villa P, Namer IJ, Dontenwill M, Guenot D, Entz-Werle N

Cancers (Basel). 2019 Nov 26;11(12):

RNA Aptamers Targeting Integrin α5β1 as Probes for Cyto- and Histofluorescence in Glioblastoma.

Fechter P, Cruz Da Silva E, Mercier MC, Noulet F, Etienne-Seloum N, Guenot D, Lehmann M, Vauchelles R, Martin S, Lelong-Rebel I, Ray AM, Seguin C, Dontenwill M, Choulier L

Mol Ther Nucleic Acids. 2019 May 24;17:63-77

Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer.

Cruz da Silva E, Dontenwill M, Choulier L, Lehmann M

Cancers (Basel). 2019 May 17;11(5):

TGF-β, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma.

Kuonen F, Surbeck I, Sarin KY, Dontenwill M, Ruegg C, Gilliet M, Oro AE, Gaide O

J. Invest. Dermatol.. 2018 May 11;:

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers.

Mercier MC, Dontenwill M, Choulier L

Cancers (Basel). 2017 Jun;9(6):

Expression/activation of α5β1 integrin is linked to the β-catenin signaling pathway to drive migration in glioma cells.

Renner G, Noulet F, Mercier MC, Choulier L, Etienne-Selloum N, Gies JP, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M

Oncotarget. 2016 Sep;7(38):62194-62207

Glioma cell dispersion is driven by α5 integrin-mediated cell-matrix and cell-cell interactions.

Blandin AF, Noulet F, Renner G, Mercier MC, Choulier L, Vauchelles R, Ronde P, Carreiras F, Etienne-Selloum N, Vereb G, Lelong-Rebel I, Martin S, Dontenwill M, Lehmann M

Cancer Lett.. 2016 07;376(2):328-38

Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro.

Akasov R, Zaytseva-Zotova D, Burov S, Leko M, Dontenwill M, Chiper M, Vandamme T, Markvicheva E

Int J Pharm. 2016 Jun;506(1-2):148-57

Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties.

Jung AC, Ray AM, Ramolu L, Macabre C, Simon F, Noulet F, Blandin AF, Renner G, Lehmann M, Choulier L, Kessler H, Abecassis J, Dontenwill M, Martin S

Oncotarget. 2015 Oct 12

Integrin alpha5beta1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Renner G, Janouskova H, Noulet F, Koenig V, Guerin E, Bar S, Nuesch J, Rechenmacher F, Neubauer S, Kessler H, Blandin AF, Choulier L, Etienne-Selloum N, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M

Cell Death Differ. 2015 Oct 16

β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.

Blandin AF, Renner G, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M

Front Pharmacol. 2015 ;6:279

Single cell tracking assay reveals an opposite effect of selective small non-peptidic alpha5beta1 or alphavbeta3/beta5 integrin antagonists in U87MG glioma cells.

Ray AM, Schaffner F, Janouskova H, Noulet F, Rognan D, Lelong-Rebel I, Choulier L, Blandin AF, Lehmann M, Martin S, Kapp T, Neubauer S, Rechenmacher F, Kessler H, Dontenwill M

Biochim Biophys Acta. 2014 Sep;1840(9):2978-87

Quantitative measurement of delivery and gene silencing activities of siRNA polyplexes containing pyridylthiourea-grafted polyethylenimines.

Pinel S, Aman E, Erblang F, Dietrich J, Frisch B, Sirman J, Kichler A, Sibler AP, Dontenwill M, Schaffner F, Zuber G

J Control Release. 2014 May 28;182:1-12

Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target alpha5 integrin in colon cancer cells.

Janouskova H, Ray AM, Noulet F, Lelong-Rebel I, Choulier L, Schaffner F, Lehmann M, Martin S, Teisinger J, Dontenwill M

Cancer Lett. 2013 Aug 19;336(2):307-18

Integrin alpha5beta1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.

Schaffner F, Ray AM, Dontenwill M

Cancers (Basel). 2013 Jan 15;5(1):27-47

Involvement of the TGFbeta pathway in the regulation of alpha5 beta1 integrins by caveolin-1 in human glioblastoma.

Cosset EC, Godet J, Entz-Werle N, Guerin E, Guenot D, Froelich S, Bonnet D, Pinel S, Plenat F, Chastagner P, Dontenwill M, Martin S

Int J Cancer. 2012 Aug 1;131(3):601-11

Methylation of imidazoline related compounds leads to loss of alpha(2)-adrenoceptor affinity. Synthesis and biological evaluation of selective I(1) imidazoline receptor ligands.

Schann S, Greney H, Gasparik V, Dontenwill M, Rascente C, Lacroix G, Monassier L, Bruban V, Feldman J, Ehrhardt JD, Bousquet P

Bioorg Med Chem. 2012 Aug 1;20(15):4710-5

Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.

Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N, Lehmann-Che J, Godet J, Martin S, Teisinger J, Dontenwill M

Cancer Res. 2012 Jul 15;72(14):3463-70

Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo.

Creusat G, Thomann JS, Maglott A, Pons B, Dontenwill M, Guérin E, Frisch B, Zuber G

J Control Release. 2012 Feb;157(3):418-26

Integrins and p53 pathways in glioblastoma resistance to temozolomide.

Martin S, Janouskova H, Dontenwill M

Front Oncol. 2012;2:157

alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells.

Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K, Martin S, Dontenwill M

Int J Cancer. 2010 Sep 1;127(5):1240-8.

Liquid ordered phase in cell membranes evidenced by a hydration-sensitive probe: effects of cholesterol depletion and apoptosis.

Oncul S, Klymchenko AS, Kucherak OA, Demchenko AP, Martin S, Dontenwill M, Arntz Y, Didier P, Duportail G, Mely Y

Biochim Biophys Acta. 2010 Jul;1798(7):1436-43

Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist.

Martin S, Cosset EC, Terrand J, Maglott A, Takeda K, Dontenwill M

Biochim Biophys Acta. 2009 Feb;1793(2):354-67